ARCHIVES

Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC

This article is from The Cancer Letter archive.

Vol. 38 No. 32 | August 10, 2012

Download PDF Visit The Full Archive

Related Articles

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

FDA Staff Efforts To Issue Warning Letters On Procrit Ads Were Stopped By Counsel.

May 9, 2008

BCDDP “Major Accomplishment” Described By ACS’ Holleb

July 21, 1978

The NLST at a Glance

August 2, 2013

Wynder’s Low Fat Adjuvant Breast Cancer Study Finally Funded

October 21, 1988

In Brief: House Passes Bill Extending Saccharin Status To 1981; Execs No Enthusiastic Over New SES

August 3, 1979